1-8 of 8
J. Greg Slatter
Close
Sort by
Journal Articles

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

Lu Zhang, Bill Poland, Shuang Xu, Martine Allard, Cecile Krejsa, J. Greg Slatter
Journal: Blood
Blood (2023) 142 (Supplement 1): 5755.
https://doi.org/10.1182/blood-2023-174749
Published: 2023
Journal Articles

An Enterohepatic Recirculation Population Pharmacokinetic and MIC-1 Pharmacokinetic-Pharmacodynamic Model for the MDM2 Inhibitor Navtemadlin (KRT-232) in Healthy Subjects

Lu Zhang, Bill Poland, Michelle Green, Shekman Wong, J. Greg Slatter
Journal: Blood
Blood (2021) 138 (Supplement 1): 4350.
https://doi.org/10.1182/blood-2021-145205
Published: 2021
Journal Articles

A Mechanistic Physiologically Based Pharmacokinetic (PBPK) Drug Interaction Model for the Mouse Double Minute 2 (MDM2) Inhibitor KRT-232

Ian E. Templeton, PhD, Terry Podoll, PhD, Cecile Marie Krejsa, PhD, J. Greg Slatter, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-135987
Published: 2020
Journal Articles

Effect of Food on MDM2 Inhibitor KRT-232 Pharmacokinetics and Macrophage Inhibitory Cytokine-1 (MIC-1) Response in Healthy Volunteers

Shekman Wong, PhD, Cecile Marie Krejsa, PhD, Dana Lee, PharmD, Anna Harris, Emilie Simard, MSc, Xiaohui Wang, Igor Rubets, PhD, Martine Allard, PharmD, PhD, Terry Podoll, PhD, Terry O'Reilly, MD, J. Greg Slatter, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-135985
Published: 2020
Journal Articles

Exposure-Response of the Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in the Treatment of Hematologic Malignancies

Feng Jin, PhD, Ming Yin, PhD, Vinay Mandava, Helena Edlund, PhD, Marilee Andrew, PhD, Priti Patel, MD, Eric Masson, PharmD, Nidal Al-Huniti, PhD, Xiaolin Wang, ScD, J. Greg Slatter, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1268.
https://doi.org/10.1182/blood.V130.Suppl_1.1268.1268
Published: 2017
Journal Articles

Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 Study

Michael Wang, MD, Simon Rule, MD, Pier Luigi Zinzani, MD PhD, Andre Goy, MD, Rene-Olivier Casasnovas, MD, Stephen D. Smith, MD, Gandhi Damaj, MD, Jeanette K. Doorduijn, MD PhD, Thierry Lamy, Pr, MD PhD, Franck Morschhauser, MD PhD, Carlos Panizo, MD PhD, Bijal Shah, MD, Andrew Davies, PhD, Richard Eek, MBCHB, Jehan Dupuis, MD, Eric Jacobsen, MD, Arnon P. Kater, MD PhD, Steven Le Gouill, MDPhD, Lucie Oberic, MD, Tadeusz Robak, MD PhD, Todd Covey, PhD, Richa Dua, PharmD, Ahmed Hamdy, MD, Xin Huang, Raquel Izumi, PhD, Priti Patel, MD, J. Greg Slatter, PhD, Wojciech Jurczak, PhDMD
Journal: Blood
Blood (2017) 130 (Supplement 1): 155.
https://doi.org/10.1182/blood.V130.Suppl_1.155.155
Published: 2017
Journal Articles

CYP3A-Mediated Drug Interaction Profile of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib

Raquel Izumi, PhD, Paul G. Pearson, PhD, Ahmed Hamdy, MD, Sara Rodriquez, MHA, Yolanda Y.L. Yang, MD PhD, Roger G. Ulrich, PhD, Terry Podoll, PhD, Marilee Andrew, PhD, Cecile M. Krejsa, PhD, Tim Ingallinera, BSc, J. Greg Slatter, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4996.
https://doi.org/10.1182/blood.V130.Suppl_1.4996.4996
Published: 2017
Journal Articles

Population Pharmacokinetics of Bruton Tyrosine Kinase Inhibitor, Acalabrutinib, in Healthy Volunteers and Patients with B-Cell Malignancies

Helena Edlund, PhD, Marilee Andrew, PhD, Feng Jin, PhD, Priti Patel, MD, Eric Masson, PharmD, J. Greg Slatter, PhD, Sergey Aksenov, PhD, Nidal Al-Huniti, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4997.
https://doi.org/10.1182/blood.V130.Suppl_1.4997.4997
Published: 2017